Adipogen/L-NMMA . monoacetate/AG-CR1-3578-M005/5 mg
商品编号：
AG-CR1-3578-M005
品牌：
Adipogen Inc
市场价：
¥400.00
美元价：
240.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | NG-Monomethyl-L-arginine . monoacetate |
| Product Type | Chemical |
| Properties | |
| Formula | C7H16N4O2 . CH3COOH |
| MW | 188.2 . 60.1 |
| Merck Index | 14: 6022 |
| CAS | 53308-83-1 |
| RTECS | RM2982000 |
| Purity Chemicals | ≥99% (TLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in water, ethanol, methanol or DMSO. |
| InChi Key | IKPNWIGTWUZCKM-JEDNCBNOBD |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Endothelium-derived relaxing factor inhibitor. Inhibits the generation of NO from arginine.
- Competitive, irreversible non-selective inhibitor of all three NOS I, II, and III isoforms (eNOS, iNOS and nNOS).
- Inhibits the synthesis of nitric oxide (NO) in a dose-dependent and enantiospecific fashion.
- Useful tool to study the role and the effects of NO in cardiovascular and gastrointestinal disorders, hypertension, diabetes, septic shock, inflammation, infection, stroke and neurodegenerative disorders.
Product References
- Identification of arginine as a precursor of endothelium-derived relaxing factor: I. Sakuma, et al.; PNAS 85, 8664 (1988)
- NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo?: K. Aisaka, et al.; BBRC 160, 881 (1989)
- A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation: D.D. Rees, et al.; Br. J. Pharmacol. 96, 418 (1989)
- Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo: D.D. Rees, et al.; Br. J. Pharmacol. 101, 746 (1990)
- Role of endothelium-formed nitric oxide on vascular responses: J. Marin J & C.F. Sanchez-Ferrer; Gen. Pharmacol. 21, 575 (1990)
- Inactivation of macrophage nitric oxide synthase activity by N(G)-methyl-L-arginine: N.M. Olken, et al.; BBRC 177, 828 (1991)
- Nitric oxide: an endogenous modulator of leukocyte adhesion: P. Kubes, et al.; PNAS 88, 4651 (1991)
- Macrophage nitric oxide mediates immunosuppression in infectious inflammation: T.K. Eisenstein, et al.; Immunobiology 191, 493 (1994) (Review)
- N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a differential pattern of inactivation toward the three nitric oxide synthases: D.W. Reif & C.A. McCreedy; Arch. Biochem. Biophys. 320, 170 (1995)
- Cell death, survival and proliferation in Tetrahymena thermophila. Effects of insulin, sodium nitroprusside, 8-Bromo cyclic GMP, NG-methyl-L-arginine and methylene blue: S.T. Christensen; Cell Biol. Int. 20, 653 (1996) (Review)
- Nitric oxide synthase inhibitors: Amino acids. O.W. Griffith & R.G. Kilbourn; Methods Enzymol. 268, 375 (1996)
- Selective inhibitors of neuronal nitric oxide synthase-is no NOS really good NOS for the nervous system? P.K. Moore & R.L. Handy; TIPS 18, 204 (1997) (Review)
- Asymmetric dimethylarginine (ADMA) and other endogenous nitric oxide synthase (NOS) inhibitors as an important cause of vascular insulin resistance: K. Toutouzas; Horm. Metab. Res. 40, 655 (2008) (Review)
- Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats: A.D. Baron; Am. J. Physiol. 269, E709 (1995)
- The NO synthase inhibitors L-Name and L-NMMA, but not L-arginine, block the mammalian nicotinic acetylcholine receptor channel: M Scheller; Toxicol. Lett. 100-101, 109 (1998)
- Induction of apoptosis by L-NMMA, via FKHRL1/ROCK pathway in human gastric cancer cells: Y.Z. Wang & Z.Q. Feng; Biomed. Environ. Sci. 19, 285 (2006)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
